Clinical trials: MSS/pMMR
Rectal Cancer
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
This study aims to evaluate the effectiveness and safety of combining moderately hypofractionated radiotherapy with chemotherapy and anti-PD-1 antibodies as a neoadjuvant treatment for high-risk locally advanced rectal cancer.
- Trial name
- iMHRT-LARC (NCT06599827)
- Testing
- moderately hypofractionated radiotherapy, chemotherapy, immunotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Rectal Cancer, Radiation
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Primary Objectives： Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR/MSS mid - low rectal cancer.
- Conditions
- Rectal Cancer, Radiation, AK112
- Trial name
- STAR (NCT07162714)
- Testing
- radiotherapy, Ivonescimab (20mg/kg Q3W), Non-operative Management
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
pMMR, MSS
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Colorectal cancer of Mismatch Repair-proficient (pMMR)/ Microsatellite Stability (MSS) accounts for approximately 85% of all colorectal cancer patients, which might be insensitive to immunotherapy.
- Conditions
- pMMR, MSS, MSI-L, Locally Advanced Rectal Carcinoma
- Trial name
- NCT05731726
- Testing
- Serplulimab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Colorectal Cancer Liver Metastases
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients
- Trial name
- NCT05588297
- Testing
- CapOx(Capecitabine+ Oxaliplatin), Bevacizumab, Nivolumab
- Volunteers
- 12 people
- Sponsor
- Shanghai Changzheng Hospital
Colorectal Cancer
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.
- Trial name
- NCT07137390
- Testing
- Regorafenib, Lorigerlimab
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
The efficacy of combining TKI with PD-1 inhibitor in the treatment of advanced MSS/pMMR colorectal cancer with low levels of maxVAF in peripheral blood ctDNA failed with standard treatment was assessed, compared to standard…
- Trial name
- NCT06543836
- Testing
- Sintilimab, Fruquintinib or Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colon Adenocarcinoma
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally…
- Trial name
- TRIUNITE-08 (NCT07468630)
- Testing
- Tolecizumab (PCSK9 Inhibitor), Sintilimab
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Colorectal Cancer (CRC)
A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer
This study aims to evaluate the safety, tolerability, and efficacy of pirfenidone and PD-1 monoclonal antibody combined with or without hypofractionated radiotherapy in the treatment of advanced refractory pMMR/MSS colorectal…
- Trial name
- NCT07644286
- Testing
- Pirfenidone in combination with a PD-1 inhibitor, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Tao Zhang
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
There are several basic findings in the previous studies: The levels of renin and aldosterone in the blood of cancer patients vary greatly among individuals, and the baseline levels of some patients are relatively higher than…
- Trial name
- EAPPA (NCT06992024)
- Testing
- Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.
- Trial name
- ETC-159-02 (NCT06513624)
- Testing
- ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid
- Where
- 2 sites in Singapore
- Volunteers
- 16 people
- Sponsor
- National University Hospital, Singapore
Colon Cancer, PCSK9 Inhibitor
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally…
- Conditions
- Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy
- Trial name
- TRIUNITE-08 (NCT07840677)
- Testing
- Tafolecimab, Sintilimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Immune Checkpoint Therapy, Radiotherapy
Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
The current standard first-line treatment for metastatic colorectal cancer is chemotherapy combined with targeted therapy, yet the prognosis remains poor.
- Conditions
- Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)
- Trial name
- NCT06958419
- Testing
- Node-Sparing Radiotherapy plus first-line therapy, First-line treatment
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colon Adenocarcinoma
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
- Trial name
- NCT06709885
- Testing
- Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Metastatic Colorectal Cancer (CRC)
The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.
The goal of this clinical trial is to verify the effectiveness and safety of Lactobacillus johnsonii in combination with CapeOX and Pembrolizumab for the treatment of MSS/pMMR metastatic colorectal cancer (CRC).
- Trial name
- MSSpMMRCapeOX (NCT06823323)
- Testing
- Lactobacillus johnsonii
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
This is an open-label, single-arm, single-center phase II clinical study, aiming to investigate the safety and efficacy of Aipalolitovorelizumab (QL1706) combined with bevacizumab plus standard chemotherapy regimen as first-line…
- Trial name
- NCT07229846
- Testing
- Aipalolitovorelizumab, XELOX + Bevacizumab, mFOLFOX + Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Rectal Cancer, Neoadjuvant Therapies
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06958432
- Testing
- Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor, Conventional Radiotherapy plus Chemotherapy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Adenocarcinoma
A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of short-course radiotherapy followed by ivonescimab and chemotherapy in participants with pMMR/MSS locally advanced rectal cancer.
- Trial name
- NCT06919510
- Testing
- lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic, MSS
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
REGONIVO is a Phase Ib study to explore the efficacy and safety of regorafenib in combination with nivolumab in the treatment of gastric cancer and colorectal cancer with MSS.
- Trial name
- NCT04030260
- Testing
- Regorafenib and PD-1 antibody in Combination with Radiotherapy, Radiation therapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer…
- Trial name
- NCT07079631
- Testing
- BNT314, Pumitamig, SoC chemotherapy treatment 1
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 482 people
- Sponsor
- BioNTech SE